Eli Lilly recorded a 41.5% growth in fourth-quarter profits ending December 31, according to the company’s press release. The earnings were boosted by higher demand for its diabetes drugs and a successful launch of the Covid-19 antibody treatment.
- Eli’s net earnings rose to $2.12 billion or $2.32 per share in the fourth quarter, up from $1.50 billion or $1.64 per share from a year earlier.
- The full-year EPS declined to $6.79 or $7.93 on a non-GAAP basis.
- The company guided its 2021 GAAP EPS to be in the range of $7.10 to $7.75 to reflect recent business development activities.
- The company had worldwide revenue of $871.2 million in the fourth quarter for bamlanivimab, its Covid-19 antibody therapy.
Eli Lilly stock is gaining on the earnings release. LLY: NYSE is up 4.52% on premarket.
